Promore Pharma
16.11.2021 15:07:45 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 16, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Promore Pharma AB (publ) today announced the composition of the Nomination Committee for the Annual General Meeting 2022, which will be held on Tuesday 17 May 2022. The Nomination Committee shall, according to decided principles for the appointment of the Nomination Committee, consist of the Chairman of the Board and representatives for the three largest shareholders in the company.
The main task of the Nomination Committee is to submit proposals for Chairman of the Board and other members of the Board, remuneration for Board work, the election and remuneration of auditors. The Nomination Committee shall be composed of the Chairman of the Board and members appointed by the three largest shareholders in the company based on ownership of the Company as per the end of September 2021.
Accordingly, the following committee members have been appointed:
- Göran Pettersson, Chairman of the Board
- David Sundin, representing Corespring New Technology AB (former Midroc New Technology)
- Henric Rahm, representing PharmaResearch Co. Ltd
- Hans-Peter Ostler, representing a co-registered group of shareholders, with an ownership equivalent to 8.2% of the company
The Nomination Committee's proposals will be presented in the Notice to the AGM 2022 and on the company web site, www.promorepharma.com. Shareholders desiring to submit comments or proposals to the nomination committee can send them via email to info@promorepharma.com.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/673114/Nomination-Committee-Appointed-for-the-Annual-General-Meeting-2022-in-Promore-Pharma
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Loar Holdings Inc. Reports Q1 2026 Record Results and Upward Revision to 2026 Outlook7.5.2026 14:30:00 CEST | Press release
WHITE PLAINS, NY / ACCESS Newswire / May 7, 2026 / Loar Holdings Inc. (NYSE:LOAR) (the "Company," "Loar," "we," "us" and "our"), reported record results for the first quarter of 2026. First Quarter 2026 Net sales of $156.1 million, up 36.1% compared to the prior year's quarter. Net income of $11.1 million, compared to $15.3 million for the prior year's quarter, primarily resulting from higher interest, higher non-cash amortization of acquired intangible assets, and the non-recurring non-cash recognition of inventory step-up related to the LMB and Harper Engineering acquisitions. Diluted earnings per share of $0.12 compared to $0.16 for the prior year's quarter, primarily resulting from higher interest, higher amortization of acquired intangible assets, and the non-recurring non-cash recognition of inventory step-up related to the LMB and Harper Engineering acquisitions. Adjusted EBITDA of $63.2 million, up 46.6% compared to the prior year's quarter. Net income margin of 7.1% compared t
Able Device Introduces SIMbae(TM), Enabling Deterministic AI Execution at the Identity Layer7.5.2026 14:15:00 CEST | Press release
From Connectivity Management to Execution. AI predicts. SIMbae enforces. RALEIGH, NC / ACCESS Newswire / May 7, 2026 / Able Device today announced a major evolution of its SIMbae™ technology, introducing AI-driven connectivity execution directly within the SIM/eSIM secure element - transforming the SIM into a deterministic enforcement engine for intelligent mobile networks. Across the telecom industry, artificial intelligence is rapidly being adopted to analyze network data, predict device behavior, and recommend connectivity optimizations. However, a critical gap remains: while AI generates insights, there has been no universal mechanism to enforce those decisions consistently across devices, networks, and geographies. SIMbae closes that gap. By embedding deterministic policy execution inside the SIM - the most widely deployed secure element - SIMbae turns AI insight into real-world device behavior without requiring applications or device firmware changes. AI predicts. SIMbae enforces
AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 20267.5.2026 14:00:00 CEST | Press release
How decision velocity closes the gap between insight and action in complex, fast-moving supply chains ANTWERPEN, BE / ACCESS Newswire / May 7, 2026 / OMP, a leader in AI-powered supply chain planning, brings AstraZeneca to the Gartner Supply Chain Symposium/Xpo™ 2026 in Barcelona. Together, they will share how AstraZeneca is transforming planning to keep pace with increasing complexity and constant change - building an integrated, decision-centric approach powered by OMP's Unison Planning™ platform and UnisonIQ AI orchestration. AstraZeneca's journey to decision-centric planning Diane Gorman, Network Supply Planner at AstraZeneca, takes the Gartner stage to share how the global biopharmaceutical company is evolving from spreadsheet-based planning to integrated, capacity-aware decision-making. The session covers how this shift improves visibility into constraints and strengthens outcomes across campaign management, capacity planning, and detailed scheduling. Gorman will address: What it
How to Clear the Strait of Hormuz from the Air: UMag Solutions Launches F1Mag(R) - an Unmanned Solution for Rapid Naval Mine Detection and Anti-Submarine Warfare7.5.2026 13:55:00 CEST | Press release
BIRKERØD, DK / ACCESS Newswire / May 7, 2026 / F1Mag® extends UMag's drone-based magnetic sensing portfolio with a high-speed, airborne system for real-time detection of naval mines and submarines in open-sea environments, covering up to 6,000 hectares per hour, without placing marine vessels and personnel at risk. Why this matters now As Iranian sea mines remain unaccounted for in the Strait of Hormuz, NATO's Baltic Sentry mission scales up patrols of subsea infrastructure, and Black Sea drift mines continue to threaten civilian shipping, UMag Solutions today launches F1Mag®, an airborne magnetic sensing system that lets defence operators detect naval mines, submarines and uncrewed underwater vehicles (UUVs) from the air - at speeds of up to 120 km/h, without deploying anything into the water. After more than a year of testing with both naval and army units, F1Mag® is now officially launched. F1Mag® can be mounted on any drone and flown over the area of interest. It detects the magnet
Polaris Renewable Energy Announces Q1 2026 Results7.5.2026 13:50:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / May 7, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris Renewable Energy" or the "Company"), is pleased to report its financial and operating results for the quarter ended March 31, 2026. This earnings release should be read in conjunction with the Company's consolidated financial statements and management's discussion and analysis, which are available on the Company's website at www.PolarisREI.com and have been posted on SEDAR+ at www.sedarplus.ca. The dollar figures below are denominated in US Dollars unless noted otherwise. HIGHLIGHTS For the quarter ended March 31, 2026 consolidated energy production decreased by 5% compared to the same quarter in 2025, with total production of 205,317 MWh versus 216,344 MWh for the quarter ended March 31, 2025. The decrease was attributable to the scheduled major maintenance in Nicaragua, with no major maintenance in the comparative period, as well as higher curtailment in the Dominican Republic. This was pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom